XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country ...Middle East

- Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved...

Hence then, the article about xpovio selinexor approved for new indication in dlbcl in china bringing a new treatment option to patients in the country was published today ( Friday 05/07/2024 - 04:14 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country )

Also on site :

• Serious crash shuts down multiple lanes in western suburb
• Trump vows to get Iran’s enriched uranium
• Trump rejects Iran response to US war-ending proposal